New myeloma study IDs key factors for stem cell transplant outcomes
Number of stem cells given, not chemotherapy dose, tied to treatment's effects
Written by |
For people with myeloma who undergo a stem cell transplant using their own cells, the key determinant of the treatment’s effects is the number of stem cells given during the procedure, according to a new study involving more than 120 patients.
The researchers found that the chemotherapy dose used to prepare for the transplant — part of a pretreatment process known as conditioning — was not tied to the transplants’ outcomes.
“After adjustment for baseline clinical differences, infused [stem] cell dose emerged as the strongest independent predictor of hematopoietic [blood cell] recovery and transfusion burden, whereas [chemotherapy] dose was not independently associated with these outcomes,” the researchers wrote.
The team concluded that the number of stem cells administered may have a greater effect on outcomes than the chemotherapy dose given to prepare for the transplant.
The study, “Impact of Melphalan Conditioning Dose and Infused CD34⁺ Cell Dose on Engraftment Kinetics, Transfusion Requirements, and Early Transplant Outcomes Following Autologous Stem Cell Transplantation for Multiple Myeloma,” was published in the Indian Journal of Hematology and Blood Transfusion by a research team in India.
Myeloma is a form of blood cancer marked by the abnormal growth of certain immune cells in the bone marrow, the spongy tissue inside certain bones. To help control this cancer, doctors often use hematopoietic stem cell transplantation, known as HSCT — a mainstay of treatment for myeloma.
First, healthy stem cells are collected from the patient. The individual then undergoes high-dose chemotherapy, called conditioning, to wipe out as many cancer cells as possible. Because this heavy chemotherapy also temporarily destroys the bone marrow’s ability to produce blood cells, the collected stem cells are reinfused to rebuild a healthy blood and immune system.
While not a permanent cure, HSCT can provide long-lasting disease remission. However, conditioning regimens are very intensive and carry substantial safety risks, the researchers noted.
Conditioning treatments often use chemo agent called melphalan
A specific chemotherapy agent, melphalan, is commonly used for conditioning regimens in myeloma. However, it remains unclear what the best dosing strategy for this medication is. The standard dose is 200 mg/m2, but lower doses (e.g., 140 mg/m2) are often used when safety is a major concern, with the goal of minimizing treatment-related toxicities.
“Melphalan remains the backbone of conditioning therapy; however, the optimal dosing strategy continues to be debated,” the researchers wrote. “Therefore, the present study aimed to compare standard-dose and reduced-dose melphalan conditioning in patients undergoing … HSCT for multiple myeloma.”
The research team, from Apollo Multispeciality Hospitals, compared outcomes among 122 people with myeloma who underwent HSCT at their center. Among the patients, 73 received the standard dose while 49 were given the reduced dose. Individuals in the reduced-dose group were generally older and had more underlying health problems, which was expected given that the reduced dose is more often used in patients for whom safety is a major concern.
The results showed that patients in the standard-dose group had significantly faster neutrophil and platelet engraftment — in other words, these individuals began producing new immune cells, such as neutrophils, and other blood cells, including platelets, sooner after completing the transplant procedure. Patients in the standard-dose group also generally had a lower need for blood transfusions during treatment.
However, statistical analyses showed that after adjusting for age and underlying health status, melphalan dose was not significantly associated with differences in engraftment or transfusion requirements. Instead, the analyses consistently showed that patients who received a higher dose of blood stem cells after conditioning had faster engraftment and less need for transfusions.
Achieving an adequate … cell dose may have a greater impact on early transplant outcomes than conditioning intensity alone.
“Although unadjusted analyses demonstrated significantly faster neutrophil and platelet engraftment, lower transfusion requirements, and shorter hospital stay in patients receiving [the standard dose], the principal finding of the present study was that infused [blood stem] cell dose, rather than melphalan dose, emerged as the strongest independent predictor of hematopoietic recovery and transfusion burden after adjustment for baseline clinical characteristics,” the researchers concluded.
According to the team, these data support the use of personalized melphalan dosing — given that lower chemotherapy doses do not appear to be associated with worse recovery outcomes after accounting for baseline health factors.
These findings also underscore the clinical importance of optimizing stem cell mobilization to ensure an adequate stem cell dose for a transplant, the researchers noted.
“Achieving an adequate … cell dose may have a greater impact on early transplant outcomes than conditioning intensity alone,” the team wrote.
Leave a comment
Fill in the required fields to post. Your email address will not be published.